about
Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and RepairDisease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.Neuroantigen-specific autoregulatory CD8+ T cells inhibit autoimmune demyelination through modulation of dendritic cell function.Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosisClonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in multiple sclerosis.Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.Quantification of neurovascular protection following repetitive hypoxic preconditioning and transient middle cerebral artery occlusion in miceTransient regulatory T-cells: a state attained by all activated human T-cells.Autoregulatory CD8 T cells depend on cognate antigen recognition and CD4/CD8 myelin determinants.IL-21 promotes the production of anti-DNA IgG but is dispensable for kidney damage in lyn-/- mice.Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment.Repetitive hypoxic preconditioning induces an immunosuppressed B cell phenotype during endogenous protection from stroke.Preconditioning-induced CXCL12 upregulation minimizes leukocyte infiltration after stroke in ischemia-tolerant mice.Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.Perinatal chronic hypoxia induces cortical inflammation, hypomyelination, and peripheral myelin-specific T cell autoreactivity.High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assayIn vitro methotrexate as a practical approach to selective allodepletionTherapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis
P50
Q28078211-60919672-67BF-4872-AC48-6CFCCEA499EDQ33625425-6EE219AC-A2B2-49DD-AFE7-D3B509372BD0Q34075707-E0FA0165-4609-42DD-AE98-736CC5F0CBC2Q34612943-316BF385-A336-46B8-AAF8-8B68192D98BAQ34975668-003E5929-C7FF-473A-8758-D56D3F5FBB29Q35216023-A8F8E80A-0C52-4858-AA28-96B41D149AD7Q35636816-38789DEB-77AD-4DB2-A53D-CEAEF50984C0Q35792962-46B5434D-66CF-41BC-B461-1BABFA9BB687Q36255289-092CED35-C439-4DEA-B772-7922E6AE4D0DQ37158607-89432127-F6B6-4D5A-8ABF-3C55FFD71199Q38657074-57471134-D4FF-4213-9EAD-987DF4E0BDEDQ39258820-CAAF8DFC-050A-4705-9E51-110E55E32F0FQ39896010-53F189FA-1B3B-41AB-BB6E-55E07A9EE165Q48085108-58DCC7AA-A2EC-4112-A9DA-9C7A23BF334CQ48147404-4A971B6D-8C93-494F-B7B8-CC8450E6D126Q76376758-79062E96-BFB0-48FC-A1AD-BF0AD4D46DC3Q80390073-3B743D27-91B3-4E0F-91DE-C0B6880B9736Q83367385-9365EECF-07AE-4AC1-B3B8-3840942835A8
P50
description
researcher ORCID ID = 0000-0003-3542-9555
@en
wetenschapper
@nl
name
Sterling B Ortega
@ast
Sterling B Ortega
@en
Sterling B Ortega
@es
Sterling B Ortega
@nl
type
label
Sterling B Ortega
@ast
Sterling B Ortega
@en
Sterling B Ortega
@es
Sterling B Ortega
@nl
prefLabel
Sterling B Ortega
@ast
Sterling B Ortega
@en
Sterling B Ortega
@es
Sterling B Ortega
@nl
P106
P1153
7007033119
P31
P496
0000-0003-3542-9555